share_log

圣诺医药-B公布戴晓畅辞任首席战略官

Shengnuo Pharmaceutical-B Announces Dai Xiaochang's Resignation as Chief Strategy Officer

新浪港股 ·  May 19 19:50

Shengnuo Pharmaceutical-B (02257) announced that Dai Xiaochang resigned as Group Chief Strategy Officer due to personal reasons, effective May 17, 2024. Dr. Dai will continue as Executive Director and has agreed to serve as the Group's senior advisor for drug development and commercialization.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment